Zymergen
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Zymergen, founded in 2013 in Emeryville, California, was a synthetic biology company that used machine learning and lab automation to engineer microbes for industrial materials. Its first product, Hyaline, was a bio-based optical film for electronics. The company went public in April 2021, raising about $530 million, before product setbacks forced a strategy reset.
02 / Zymergen FAILURE REASONS
Failure reasons
Zymergen's core product Hyaline failed: production was discontinued in November 2021 after the film underperformed, wiping out the revenue story behind the $530 million IPO and triggering shareholder litigation. A go-private sale to Ginkgo Bioworks for $300 million in stock in October 2022 did not stop the bleeding; continued losses and litigation liabilities forced the subsidiary into Chapter 11 in October 2023, and a liquidation plan was confirmed in February 2024 after the assets were sold to Ginkgo and Pivot Bio. This concerns Zymergen's product and financing decisions.
03 / EVENT HISTORY
Events in the structured record
- Company founded
Zymergen is founded to apply machine learning and automation to bio-based materials and chemicals.
- Peak funding round
Zymergen goes public in April 2021, raising about $530 million; Hyaline production is discontinued in November after product issues.
- Acquisition
Ginkgo Bioworks agrees in July 2022 to acquire Zymergen for $300 million in an all-stock deal, completed in October.
- Bankruptcy filing
On October 3, 2023, Zymergen files for Chapter 11 in Delaware; a liquidation plan is confirmed on February 5, 2024 after asset sales to Ginkgo and Pivot Bio.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Machine learning meets bio-manufacturing
- 02
$530M IPO on the Hyaline story, April 2021
- 03
Hyaline discontinued; shareholder suits
- 04
Ginkgo buyout, then Chapter 11 and liquidation